Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05999630 · ClinicalTrials.gov registry record · Phase 3
Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer
A Phase 3 study of Thyroid Cancer and Nasolacrimal Duct Obstruction, sponsored by Vanderbilt University Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05999630 is a Phase 3 study of Thyroid Cancer and Nasolacrimal Duct Obstruction that is actively recruiting participants, run by Vanderbilt University Medical Center. The registered enrollment target is 100 participants, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (64% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05999630, a Phase 3 study of Thyroid Cancer and Nasolacrimal Duct Obstruction, is actively recruiting participants, sponsored by Vanderbilt University Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. It is possible that radioactive uptake by the cells in the lacrimal sac and nasolacrimal duct lead to inflammation, fibrosis, and obstruction of the tear duct over time. A recent study has shown that the administration of artificial tears decreases the level of detectable radioiodine in the tears of patients undergoing radioiodine therapy for thyroid cancer. The purpose of this study will be to assess whether administering tears after radioactive iodine therapy for thyroid cancer decreases the incidence of nasolacrimal duct obstruction in the two years following radioactive iodine treatment.
Conditions Studied
Interventions
- DRUG Artificial Tears Methylcellulose
Study Locations (1)
Tennessee
- Vanderbilt University Medical Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2023-08-21 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05999630
The ClinicalTrials.gov registry entry for NCT05999630 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 280-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (64% lower). The listed sponsor is Vanderbilt University Medical Center, which has 677 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Artificial Tears Methylcellulose is the first listed.
NCT05999630 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT05999630 about?
NCT05999630 is a clinical study titled "Artificial Tears to Prevent Nasolacrimal Duct Obstruction in Patients Treated With Radioactive Iodine for Thyroid Cancer". The association of radioiodine therapy for the treatment of thyroid cancer with nasolacrimal duct obstruction has been well documented in the medical literature. Prior case reports have documented radioactive iodine detection in the tears of patients following radioiodine therapy. It is possible tha...
What is the current status of trial NCT05999630?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 100 participants. The study started on 2023-08-21. Estimated completion is 2027-12-31.
What conditions does trial NCT05999630 study?
This clinical trial studies the following conditions: Thyroid Cancer, Nasolacrimal Duct Obstruction.
What interventions are being tested in trial NCT05999630?
The interventions under investigation include: Artificial Tears Methylcellulose (DRUG).
Who is sponsoring clinical trial NCT05999630?
This trial is sponsored by Vanderbilt University Medical Center, which has 677 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05999630 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
COMPLETED · Phase 3
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)
COMPLETED · Phase 3
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
RECRUITING · Phase 1
-
Brodalumab in the Treatment of Immune-Related Adverse Events
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.